/ARAV

ARAV Stock - Aravive, Inc.

Q: What is the analyst price target for ARAV?

Analyst price target information is not currently available for ARAV.

Q: What is ARAV's market cap?

Market capitalization information is not currently available for ARAV.

Healthcare|Biotechnology|NASDAQ

$0.04-13.39%

$0.01 (-13.39%) • Jan 26

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+523.4%upside

Target: $0.25

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ARAV

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.19

52W High$2.46

52W Low$0.04

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$9.14M	$7.44M	$5.68M	$4.75M	$1.37M
Gross Profit	$-57,801,000	$-30,099,000	$-11,935,000	$-8,083,000	$1.37M
Gross Margin	-632.6%	-404.4%	-209.9%	-170.1%	100.0%
Operating Income	$-70,837,000	$-40,649,000	$-30,784,000	$-21,774,000	$-75,412,000
Net Income	$-80,921,000	$-38,140,000	$-34,243,000	$-20,254,000	$-76,333,000
Net Margin	-885.6%	-512.5%	-602.3%	-426.1%	-5567.7%
EPS	$-2.22	$-1.90	$-2.17	$-1.75	$-10.64

Company Overview

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

2 Bullish0 Neutral/Bearish

Price Targets

$14

Average Target

↑ 33565.8% Upside

Now

$12

Low

$14

Average

$15

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
April 17th 2023	BTIG Research	Resumed	Buy	$12
June 3rd 2022	ROTH Capital	Initiation	Buy	$15

Earnings History & Surprises

ARAV

Beat Rate

65%

Last 20 quarters

Avg Surprise

-13.6%

EPS vs Estimate

Beats / Misses

13/7

Last 12 quarters

Latest EPS

$-0.46

Q1 2024

EPS Surprise History

Q2 22

-17.0%

$-0.62vs$-0.53

Q3 22

+1.6%

$-0.61vs$-0.62

Q4 22

+20.3%

$-0.51vs$-0.64

Q1 23

-39.4%

$-0.46vs$-0.33

Q2 23

+33.3%

$-0.22vs$-0.33

Q3 23

+60.0%

$-0.12vs$-0.30

Q4 23

+58.3%

$-0.10vs$-0.24

Q1 24

-475.0%

$-0.46vs$-0.08

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2024	Mar 20, 2024	$-0.08	$-0.46	-475.0%	✗ MISS
Q4 2023	Nov 9, 2023	$-0.24	$-0.10	+58.3%	✓ BEAT
Q3 2023	Aug 21, 2023	$-0.30	$-0.12	+60.0%	✓ BEAT
Q2 2023	May 10, 2023	$-0.33	$-0.22	+33.3%	✓ BEAT
Q1 2023	Mar 15, 2023	$-0.33	$-0.46	-39.4%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.64	$-0.51	+20.3%	✓ BEAT
Q3 2022	Aug 11, 2022	$-0.62	$-0.61	+1.6%	✓ BEAT
Q2 2022	May 12, 2022	$-0.53	$-0.62	-17.0%	✗ MISS
Q1 2022	Mar 31, 2022	$-0.64	$-0.62	+3.1%	✓ BEAT
Q4 2021	Oct 28, 2021	$-0.42	$-0.53	-26.2%	✗ MISS
Q3 2021	Aug 5, 2021	$-0.41	$-0.35	+14.6%	✓ BEAT
Q2 2021	May 6, 2021	$-0.45	$-0.44	+2.2%	✓ BEAT
Q1 2021	Mar 16, 2021	$-0.52	$-0.25	+51.9%	✓ BEAT
Q4 2020	Nov 5, 2020	$-0.42	$-0.66	-57.1%	✗ MISS
Q3 2020	Aug 3, 2020	$-0.45	$-0.32	+28.9%	✓ BEAT
Q2 2020	May 6, 2020	$-0.34	$-0.53	-55.9%	✗ MISS
Q1 2020	Mar 27, 2020	$-0.53	$-0.35	+34.0%	✓ BEAT
Q4 2019	Nov 7, 2019	$-0.50	$-0.54	-8.0%	✗ MISS
Q3 2019	Aug 7, 2019	$-0.56	$-0.27	+51.8%	✓ BEAT
Q2 2019	May 8, 2019	$-0.79	$-0.42	+46.8%	✓ BEAT